王祥喜 / 博士 研究员 博士生导师
中国科学院生物物理研究所,生物大分子全国重点实验室副主任,研究组长
研究方向:基于抗体谱系及免疫机制开发新型/广谱疫苗
电子邮件:xiangxi@ibp.ac.cn
电  话:010-64888806
简历

2009               四川大学生物技术专业,获得理学学士学位

2014               中国科学院生物物理研究所,获得理学博士学位

2014.07 - 2014.09   中国科学院生物物理研究所,副研究员

2014.09 - 2016.02   牛津大学,访问学者

2014.10 - 至今       中国科学院生物物理研究所,研究员

获奖及荣誉

2014年  吴瑞奖学金

2014年  中国科学院青年研究员人才计划

2015年  青年人才托举工程

2015年  贝时璋青年生物物理学家奖

2020年  中国科学院青年科学家奖

2020年  中源协和生命医学创新奖

2021年  首届钟南山青年科技创新奖

2021年  谈家桢生命科学创新奖

2022年  TR35青年创新奖

2022年  第十七届中国青年科技奖

2023年  第六届中国转化医学奖

2024年  中央和国家机关青年五四奖章

社会任职
承担项目情况

  本课题组主要研究方向包括以下三方面:

1. 冠状、流感等极易突变型病毒的免疫机制研究、抗体谱系解析和广谱疫苗开发

  冠状病毒、流感病毒等高度易突变病毒可通过抗原漂移或转换逃逸宿主免疫识别,削弱传统疫苗的保护效力,因此亟待新型广谱型疫苗以建立有效的人群免疫屏障。自然感染或疫苗接种后,病毒在机体的体液免疫驱动下发生定向进化,通过更新突变株或转换主要流行株等方式继续实现宿主共存。抗体谱系分析可揭示中和抗体的发育路径、靶向表位及广谱识别机制,为优化疫苗保护性抗原设计提供依据。

  本课题组针对高度突变病毒的疫苗研发,结合了结构生物学、病毒学、免疫学和生物信息学,通过调控抗原特异性/广谱性免疫信号改造免疫原,以诱导强效、广谱中和抗体。同时利用新型疫苗技术(如mRNA、纳米颗粒等)来提高免疫原性及保护周期。此外,利用基于AI的抗原改造定向调控免疫原诱导的中和抗体谱系,优先激活成熟广谱抗体,提高交叉保护效力,为"通用疫苗"研发奠定基础。

2. 登革病毒/呼吸道合胞病毒等ADE/VAERD型病毒的免疫机制研究、抗体谱系解析和中和抗体与新型疫苗开发

  DENV和RSV等病毒可通过ADE或VAERD加剧疾病进程,使得基于传统路线开发的疫苗易引发严重的安全问题。DENV的四种血清型可诱导非中和交叉抗体,在异型病毒二次感染时促进病毒复制并加重疾病,而RSV早期灭活疫苗接种导致严重的免疫病理反应,其表面抗原的非保护性表位可能是关键诱因。

  本课题组聚焦于ADE/VAERD型病毒的免疫机制解析、抗体谱系追踪及安全性疫苗设计。通过高通量单细胞测序、深度突变扫描等技术,系统解析DENV和RSV不同时空背景自然感染及疫苗接种人群诱导的中和抗体谱系规律,识别导致ADE/VAERD的不良免疫信号和关键保护性表位。结合结构生物学与AI蛋白设计技术,稳定保护性抗原构象,屏蔽ADE不良信号,使免疫原诱导亲和力高、ADE风险低的强效中和抗体,同时避免非中和抗体的产生,从而为安全、高效的DENV及RSV疫苗研发提供理论基础和技术支持,推动突破长期困扰人类的疫苗安全性难题。

3. 非洲猪瘟病毒、疱疹病毒等成分复杂型病原体保护性抗原谱破译和强效保护性疫苗开发

  非洲猪瘟病毒(ASFV)拥有近200个编码基因,其高度复杂的衣壳和包膜蛋白影响疫苗诱导的免疫应答。本课题组解析ASFV的保护性抗原表位及其介导的体液和细胞免疫机制,有助于筛选关键免疫原,避免诱导非保护性免疫反应。疱疹病毒如HCMV、VZV、HSV-2等可长期潜伏于宿主体内,周期性激活并逃避免疫清除。本课题组基于高通量免疫学手段解析感染人群血清抗体谱系,鉴定保护性抗原集合并通过AI蛋白质设计技术开发多价疫苗。同时,利用自主知识产权的VLP与免疫原仿生展示技术,构建纳米颗粒疫苗,刺激机体诱导强效、持久的体液免疫。

2026年度

1. Zhai H#, Yu W#, Wang J#, Deng J#, Lei S, Zhou T, Li Y, Xu K, Ma M, Feng R, Hu Y, Ren L, Cao Y, Liu E*, Wang X*. Antibody cocktails based on the occupationally acquired immunity of pediatricians neutralize and confer protection against RSV and hMPV, Sci Transl Med, 2026, 18(837): eadz4170.

2. Liu P#, Xi Y#, Deng J, Luo S, Liu T, Ding C, Zhu Q, He L, Li M, Wang N*, Liu Y*, Wang X*. Designed nanoparticles enable multivalent display of influenza HA to drive rapid, potent, durable, and cross-reactive antibody responses, Protein Cell, 2026: pwag046.

3. Yu H#, Wang J#, Yue C#*, Yang X, Liu D, Zhu L, Mao X, Guo M, Song H, Hu Y,  Wang X*, Huang Y*. An internationally circulating chikungunya virus lineage with distinct mutational signatures was associated with the 2025 outbreak in China, Protein Cell, 2026, in press.

4. Liu P#, Zhu Q#, Liu J#, Ma Z#, Mou G#, Yu Y, Liu C, Ma C, Si J, Yang X, Huang M, Liu Y, Sun Y, Yu X, Sun Y, Liu T, Yu L, Wang Q, Ma H, Lv Q, Li J, Bao L*,  Cao Y*, Wang X*, Yan H*. Convergent use of aminopeptidase N receptor by hedgehog merbecoviruses, Nature Microbiology, 2026, in press.

5. Chen Y#, Liu P#, Qi F#, Wang Y#, Ren Y#, Chen Y#, Chen R, Zhang C, Chen J, Li Y, Wang L, Wang N, Jiao H, Ma X, Liu T, Yue C,  Zhu Q, Mao X, Wang S, Veit M, Wang N, Zhang Y*, Zhao L*, Bao L*, Wang X*, Su S*. Cross-species Spillover of MERS-CoV-like mink Coronaviruses driven by key spike mutations and Countermeasures Development, Nature Microbiology, 2026, accept.

6. Liu P#, Yu J#, Liu T#, Liu Y*, Wang X*. Structure-guided stabilization of the HCMV pentamer enhances thermostability and neutralizing antibody responses, Signal Transduct Target Ther, 2026, accept.

7. Chen R#, Zhang C#, Qi F#, Cao L#, Deng J, Chen Y, Liu P, Ren Y, Li Y, Wang L, Li F, Deng R, Yu Y, Mao X, Xu K, Bao L*, Cao Y*, Zhang Y*, Wang X*. Determinants of expanded ACE2 species tropism for merbecoviruses and pan-hACE2 dependent coronavirus prophylaxis, Protein Cell, 2026 , accept.

2025年度

8. Li J#, Cao L#, Zhao Y, Shen J, Wang L, Feng M, Zhu M, Ye Y, Kormelink R, Tao X*, Wang X*. Structural basis for the activation of a plant bunyavirus replication machinery and its dual-targeted inhibition by ribavirin, Nature plants, 2025, 11(3): 518-530.

9. Yu Q#, Fu W#, Zhang Z#, Liang D#, Wang L, Zhu Y, Sun E, Li F, Bu Z*, Chen Y*, Wang X*, Zhao D*. The p15 protein is a promising immunogen for developing protective immunity against African swine fever virus, Protein Cell, 2025, 16(10): 911-915.

10. Chen Z#, Feng L#, Wang L#, Zhang L#, Zheng B#, Fu H, Li F, Liu L, Lv Q, Deng R, Xu Y, Hu Y, Zheng J, Qin C, Bao L*, Wang X*, Jin Q*. A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5, Signal Transduct Target Ther, 2025, 10(1): 14.

11. Jian F#, Wec AZ#, Feng L#, Yu Y, Wang L, Wang P, Yu L, Wang J, Hou J, Berrueta DM, Lee D, Speidel T, Ma L, Kim T, Yisimayi A, Song W, Wang J, Liu L, Yang S, Niu X, Xiao T, An R, Wang Y, Shao F, Wang Y, Pecetta S, Wang X*, Walker LM*, Cao Y*. Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants, Nature Microbiology, 2025, 10(8): 2003-2017.

12. Cao L#, Qu J#, Zhang C#, Chen R, Wang J, Fehlner-Gardiner C, Niezgoda M, Satheshkumar PS, Wang X*, Tsao E*. Structural basis for broad neutralization of rabies virus by an antibody cocktail SYN023, Emerg Microbes Infect, 2025, 14(1): 2547724.

13. Hu J#, Jia Z#, Wang M, Nie L, Fu W, Zhang Q, Qin H, Nie J, Xu X, Xu L, Wang F, Chen Y, Xing B, Li T, Li D, Li S, Xia N*, Wang X*, Huang W*. Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests, NPJ Vaccines, 2025, 10(1): 55.

14. Chi H#, Zhao SQ#, Liu YP#, Xiong XC#, Zhong X#, Suo XX, Huang XY, Yue C, Zhang JJ, Cong Z, Li N, Du FX, Chen T, Ma JR, Wang L, Ying B, Deng YQ, Yin JY*, Wang X*, Xue J*, Qin CF*. Efficacy and safety of an mRNA encoding neutralizing antibody against SARS-CoV-2 in non-human primates, Sci Bull (Beijing), 2025, 70(18): 2948-2952.

15. Zhang Z#, Feng R#, Zhang L, Yang Q, Chen X, Wang X, Nie C, Peng W, Wang X, Zhu L*, Guo Y*, Sun Z*. Discovery and molecular mechanism of potent neutralizing antibody from humanized mice with respiratory syncytial virus, PLoS Pathog, 2025, 21(11): e1013674.

16. Li Y#, Wang J#*, Zhang C, Zhang Y, Deng J, Zhang H, Li M, Wang F*, Wang X*. MAAD: multidimensional antiviral antibody database, Protein Cell, 2025, 17(6): 560-572.

2024年度

17. Liu P#, Yue C#, Meng B#, Xiao T#, Yang S#, Liu S#, Jian F, Zhu Q, Yu Y, Ren Y, Wang P, Li Y, Wang J, Mao X, Shao F, Wang Y*, Gupta RK*, Cao Y*, Wang X*. Spike N354 glycosylation augments SARS-CoV-2 fitness for human adaptation through structural plasticity, National Science Review, 2024, 11(7).

18. Yue C#, Liu S#, Meng B#*, Fan K#, Yang S#, Liu P, Zhu Q, Mao X, Yu Y, Shao F, Wang P, Wang Y*, Gupta RK*, Cao Y*, Wang X*. Deletion of V483 in the spike confers evolutionary advantage on SARS-CoV-2 for human adaptation and host-range expansion after a prolonged pandemic, Cell Research, 2024, 34(10): 739-742.

19. Zhu Q#, Liu P#, Liu S#, Yue C*, Wang X*. Enhancing RBD exposure and S1 shedding by an extremely conserved SARS-CoV-2 NTD epitope, Signal Transduct Target Ther, 2024, 9(1): 217.

20. Jia Z#, Wang K#, Xie M#, Wu J#, Hu Y#, Zhou Y#*, Yisimayi A, Fu W, Wang L, Liu P, Fan K, Chen R, Wang L, Li J, Wang Y, Ge X, Zhang Q, Wu J, Wang N, Wu W, Gao Y, Miao J, Jiang Y, Qin L, Zhu L, Huang W, Zhang Y, Zhang H, Li B, Gao Q, Xie XS*, Wang Y*, Cao Y*, Wang Q*, Wang X*. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2, Protein Cell, 2024, 15(12): 930-937.

21. Feng L#, Sun Z#, Zhang Y#, Jian F, Yang S, Xia K, Yu L, Wang J, Shao F, Wang X*, Cao Y*. Structural and molecular basis of the epistasis effect in enhanced affinity between SARS-CoV-2 KP.3 and ACE2, Cell Discovery, 2024, 10(1): 123.

22. Wang Y#, Zhang Z#, Yang M#, Xiong X#, Yan Q#, Cao L#, Wei P, Zhang Y, Zhang L, Lv K, Chen J, Liu X, Zhao X, Xiao J, Zhang S, Zhu A, Gan M, Zhang J, Cai R, Zhuo J, Zhang Y, Rao H, Qu B, Zhang Y, Chen L, Dai J, Cheng L, Hu Q, Chen Y, Lv H, So RTY, Peiris M, Zhao J, Liu X*, Mok CKP*, Wang X*, Zhao J*. Identification of a broad sarbecovirus neutralizing antibody targeting a conserved epitope on the receptor-binding domain, Cell Rep, 2024, 43(1): 113653.

23. Zhao D#, Wang N#, Feng X#, Zhang Z#, Xu K, Zheng T, Yang Y, Li X, Ou X, Zhao R, Rao Z*, Bu Z*, Chen Y*, Wang X*. Transcription regulation of African swine fever virus: dual role of M1249L, Nature Communications, 2024, 15(1): 10058.

24. Yang D#, Wang N#, Du B#, Sun Z, Wang S, He X, Wang J, Zheng T, Chen Y, Wang X*, Wang J*. Structural insights into Semiliki forest virus receptor binding modes indicate novel mechanism of virus endocytosis, PLoS Pathog, 2024, 20(12): e1012770.

25. Li H#, Liu P#, Dong H#, Dekker A, Harmsen MM, Guo H*, Wang X*, Sun S*. Foot-and-mouth disease virus antigenic landscape and reduced immunogenicity elucidated in atomic detail, Nature Communications, 2024, 15(1): 8774.

26. Yu Q#, Liang D#, Fu W#, Zhang L#, Wang J#, Zhang Z#, Sun Y, Zhu D, Zheng B, Zhu L, Xiang Y, Zhao D*, Wang X*. p72 antigenic mapping reveals a potential supersite of vulnerability for African swine fever virus, Cell Discovery, 2024, 10(1): 80.

27. Liu J#, Zheng T#, Xu L#, Chen Z, Zhang K, Wang X, Xu X*, Li Y*, Sun Y*, Zhu L*. An improved method for the detection of double-stranded RNA suitable for quality control of mRNA vaccines, Protein Cell, 2024, 15(11): 791-795.

2023年度

28.  Yue C#, Song W#, Wang L, Jian F, Chen X, Gao F, Shen Z, Wang Y, Wang X*, Cao Y*. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5, The Lancet Infectious Diseases, 2023, 23(3): 278-280.

29. Ou X#, Xu G#, Li P#, Liu Y#, Zan F, Liu P, Hu J, Lu X, Dong S, Zhou Y, Mu Z, Wu Z, Wang J, Jin Q, Liu P, Lu J, Wang X*, Qian Z*. Host susceptibility and structural and immunological insight of S proteins of two SARS-CoV-2 closely related bat coronaviruses, Cell Discovery, 2023, 9(1): 78.

30. Jian F#, Feng L#, Yang S#, Yu Y#, Wang L, Song W, Yisimayi A, Chen X, Xu Y, Wang P, Yu L, Wang J, Liu L, Niu X, Wang J, Xiao T, An R, Wang Y, Gu Q, Shao F, Jin R, Shen Z, Wang Y, Wang X*, Cao Y*. Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding, PLOS Pathogens, 2023, 19(12): e1011868.

31. Li S#, Wu J#, Jiang W#, He H#, Zhou Y#, Wu W#, Gao Y#, Xie M#, Xia A, He J, Zhang Q, Han Y, Wang N, Zhu G, Wang Q, Zhang Z, Mayer CT, Wang K, Wang X*, Wang J*, Chen Z*, Jiang S*, Sun L*, Xia R*, Wang Q*. Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2: Implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies, J Med Virol, 2023, 95(2): e28440.

32. Cui Z#, Luo W#, Chen R#, Li Y#, Wang Z#, Liu Y#, Liu S, Feng L, Jia Z, Cheng R, Tang J, Huang W, Zhang Y, Liu H*, Wang X*, Li W*. Comparing T- and B-cell responses to COVID-19 vaccines across varied immune backgrounds, Signal Transduct Target Ther, 2023, 8(1): 179.

33. Dou Y#*, Xu K#, Deng YQ#, Jia Z#, Lan J#, Xu X#, Zhang G, Cao T, Liu P, Wang X, Wang X, Xu L, Du P, Qin CF, Liu H*, Li Y*, Wu G*, Wang K*, Lu B*. Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method, Antib Ther, 2023, 6(2): 76-86.

2022年度

34. Cui Z#, Liu P#, Wang N#, Wang L#, Fan K#, Zhu Q#, Wang K#, Chen R, Feng R, Jia Z, Yang M, Xu G, Zhu B, Fu W, Chu T, Feng L, Wang Y, Pei X, Yang P, Xie XS, Cao L*, Cao Y*, Wang X*. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron, Cell, 2022, 185(5): 860-871.

35. Wang K#, Jia Z#, Bao L#, Wang L#, Cao L#, Chi H#, Hu Y#, Li Q#, Jiang Y, Zhu Q, Deng Y, Liu P, Wang N, Wang L, Liu M, Li Y, Zhu B, Fan K, Fu W, Yang P, Pei X, Cui Z, Qin L, Ge P, Wu J, Liu S, Chen Y, Huang W, Qin CF*, Wang Y*, Qin C*, Wang X*. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants, Nature, 2022, 603(7903): 919-925.

36. Xiong Q#, Cao L#, Ma C#, Tortorici M#, Liu C, Si J, Liu P, Gu M, Walls A, Wang C, Shi L, Tong F, Huang M, Li J, Zhao C, Shen C, Chen Y, Zhao H, Lan K, Corti D, Veesler D*, Wang X*, Yan H*. Close relatives of MERS-CoV in bats use ACE2 as their functional receptors, Nature, 2022, 612(7941): 748-757.

37. Cao Y#*, Yisimayi A#, Jian F#, Song W#, Xiao T#, Wang L#, Du S#, Wang J#, Li Q#, Chen X#, Yu Y#, Wang P, Zhang Z, Liu P, An R, Hao X, Wang Y, Wang J, Feng R, Sun H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Song X, Chai Y, Hu Y, Shi Y, Zheng L, Li Z, Gu Q, Shao F, Huang W, Jin R, Shen Z*, Wang Y*, Wang X*, Xiao J*, Xie XS*. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection, Nature, 2022, 608(7923): 593-602.

38. Zhang Y#, Liang D#, Yuan F, Yan Y, Wang Z, Liu P, Yu Q, Zhang X, Wang X*, Zheng A*, Replication is the key barrier during the dual-host adaptation of mosquito-borne flaviviruses, PNAS, 2022, 119(12): e2110491119.

39. Li X#, Cui Z#, Hang F#, Chen Q#, Cao L#, Qiu H, Zhang N, Xu Y, Zhang R, Zhou C, Ye Q, Deng Y, Guo Y, Qin S, Fan K, Wang L, Jia Z, Cui Y*, Wang X*, Qin C*, A highly immunogenic live-attenuated vaccine candidate prevents SARS-CoV-2 infection and transmission in hamsters, Innovation(Camb), 2022, 3(2): 100221.

40. Wang L#, Fu W#, Bao L#, Jia Z#, Zhang Y#, Zhou Y#, Wu W, Wu J, Zhang Q, Gao Y, Wang K, Wang Q*, Qin C*, Wang X*, Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants, including Omicron sublineages, Cell Research, 2022, 32(7): 691-694.

41. Deng W#, Lv Q#, Li F#, Liu J#, Song Z#, Qi F, Wei Q, Yu P, Liu M, Zhou S, Zhang Y, Gao H,  Wang N, Jia Z, Gao K, Liu J, Xiao C, Shang H, Wang X*, Bao L*, Qin C*,Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques, Signal Transduct Target Ther, 2022, 7(1): 124.

42. Cao Y#*, Song W#, Wang L#, Liu P#, Yue C#, Jian F#, Yu Y, Yisimayi A, Wang P, Wang Y, Zhu Q, Deng J, Fu W, Yu L, Zhang N, Wang J, Xiao T, An R, Wang J, Liu L, Zhang N, Wang J, Xiao T, An R, Wang J, Liu L, Yang S, Niu X, Gu Q, Shao F, Hao X, Meng B, Gupta. R, Jin R, Wang Y, Xie X*, Wang X*. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75, Cell host & microbe, 2022, 30(11): 1527-1539.

43. Li Q#, Zhang L#, Liang Z#, Wang N#, Liu S#, Li T, Yu Y, Cui Q, Wu X, Nie J, Wu J, Cui Z, Lu Q, Wang X*, Huang W*, Wang Y*. Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses, Signal Transduct Target Ther, 2022, 7(1): 256.

44. Liu S#, Jia Z#, Nie J#, Liang Z#, Xie J, Wang L, Zhang L, Wang X*, Wang Y*, Huang W*. A broader neutralizing antibody against all the current VOCs and VOIs targets unique epitope of SARS-CoV-2 RBD, Cell Discovery, 2022, 8(1): 81.

45. Yang P#, Shi D#, Fu J, Zhang L, Chen R, Zheng B, Wang X, Xu S*, Zhu L*, Wang K*. Atomic Structures of Coxsackievirus B5 Provide Key Information on Viral Evolution and Survival, J Virol, 2022, 96(9): e0010522.

46. Chi H#, Wang L#, Liu C#, Cheng X#, Zheng H#, Lv L, Tan Y, Zhang N, Zhao S, Wu M, Luo D, Qiu H, Feng R, Fu W, Zhang J, Xiong X, Zhang Y, Zu S, Chen Q, Ye Q, Yan X, Hu Y, Zhang Z, Yan R, Yin J, Lei P, Wang W, Lang G*, Shao J*, Deng Y*, Wang X*, Qin C*. An Engineered IgG-VHH Bispecific Antibody against SARS-CoV-2 and Its Variants, Small Methods, 2022, 6(12): e2200932.

47. Wang M#, Sun Z#, Cui C#, Wang S, Yang D, Shi Z, Wei X, Wang P, Sun W, Zhu J, Li J, Du B, Liu Z, Wei L, Liu C, He X, Wang X*, Zhang X*, Wang J*. Structural Insights into Alphavirus Assembly Revealed by the Cryo-EM Structure of Getah Virus, Viruses, 2022, 14(2): 327.

48. Dong H#, Liu P#, Bai M, Wang K, Feng R, Zhu D, Sun Y, Mu S, Li H, Michiel H, Sun S*, Wang X*, Guo H*. Structural and molecular basis for foot-and-mouth disease virus neutralization by two potent protective antibodies, Protein Cell, 2022, 13(6): 446-453.

2021年度

49. Guo Q#, Zhao Y#, Li J#, Liu J#, Yang X#, Guo X, Kuang M, Xia H, Zhang Z, Cao L, Luo Y, Bao L, Wei X, Deng W, Wang N, Chen L, Chen J, Zhu H, Gao R, Qin, C*, Wang X*, You F*. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19, Cell Host and Microbe, 2021, 29(2): 222-235.

50. Zhu L#, Deng Y#, Zhang R#, Cui Z#, Sun C#, Fan C#, Xing X#, Huang W, Chen Q, Zhang N, Ye, Q, Cao T, Wang N, Wang L, Cao L, Wang H, Kong D, Ma J, Luo C, Zhang Y, Nie J, Sun Y, Lv Z, Shaw N, Li Q, Li X, Hu J, Xie L*, Rao Z*, Wang Y*, Wang X*, Qin C*. Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2, National Science Review, 2021, 8(3): nwaa297.

51. Zhao Y#, Kuang M#, Li J#, Zhu L#, Jia Z, Guo X, Hu Y, Kong J, Yin H, Wang X*, You F*. SARS-CoV-2 spike protein interacts with and activates TLR4, Cell Research, 2021, 31(7): 818-820.

52. Sun Y#, Wang L#, Feng R#, Wang N#, Wang Y#, Zhu D#, Xing X, Yang P, Zhang Y*, Li W*, Wang X*. Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms, Cell Research, 2021, 31(5): 597-600.

53. Zhang L#, Cao L#, Gao X#, Zheng B#, Deng Y#, Li J#, Feng R, Bian Q, Guo X, Wang N, Qiu H, Wang L, Cui Z, Ye Q, Chen G, Lu K, Chen Y, Chen Y, Pan H, Yu J, Yao W, Zhu B, Chen J, Liu Y, Qin C*, Wang X*, Zhu F*. A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2, National Science Review, 2021, 8(8): nwab053.

54. Sun S#, Gu H#, Cao L#, Chen Q#, Ye Q#, Yang G#, Li R#, Fan H#, Deng Y, Song X, Qi Y, Li M, Lan J, Feng R, Guo Y, Zhu N, Qin S, Wang L, Zhang Y, Zhou C, Zhao L, Chen Y, Shen M, Cui Y, Yang X, Wang X, Tan W, Wang H*, Wang X*, Qin C*. Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2, Nature Communications, 2021,12(1): 5654.

55. Feng R#, Wang L#, Shi D#, Zheng B, Zhang L, Hou H, Xia D, Cui L, Wang X*, Xu S*, Wang K*, Zhu L*. Structural basis for neutralization of an anicteric hepatitis associated echovirus by a potent neutralizing antibody, Cell Discovery, 2021, 7: 35.

56. Tai L#, Zhu G#, Yang M#, Cao L, Xing X, Yin G, Chan C, Qin C, Rao Z, Wang X*, Sun F*, Zhu Y*. Nanometer resolution in situ structure of the SARS-CoV-2 postfusion spike protein, PNAS, 2021, 118(48): e2112703118.

2020年度

57. Yao H#, Sun Y#, Deng Y#, Wang N#, Tan Y#, Zhang N#, Li X, Kong C, Xu Y, Chen Q, Cao T, Zhao H, Yan X, Cao L, Lv Z, Zhu D, Feng R, Wu N, Zhang W, Hu Y, Chen K, Zhang R, Lv Q, Sun S, Zhou Y, Yan R, Yang G, Sun X, Liu C, Lu X, Cheng L, Qiu H, Huang X, Weng T, Shi D, Jiang W, Shao J, Wang L, Zhang J, Jiang T, Lang G*, Qin C*, Li L*, Wang X*. Rational Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-SARS-CoVs Protection, Cell Research, 2020, 31(1): 25-36.

58. Wang N#, Sun Y#, Feng R#, Wang Y#, Guo Y#, Zhang L#, Deng Y, Wang L, Cui Z, Cao L, Zhang Y, Li W*, Zhu F*, Qin C*, Wang X*. Structure-based development of human antibody cocktails against SARS-CoV-2, Cell Research, 2020, 31(1): 101-103.

59. Lv Z#, Deng Y#, Ye Q#, Cao L#, Sun C#, Fan C#, Huang W, Sun S, Sun Y, Zhu L, Chen Q, Wang N, Nie J, Cui Z, Zhu D, Shaw N, Li X, Li Q, Xie L*, Wang Y*, Rao Z*, Qin C*, Wang X*. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody, Science, 2020, 369 (6510): 1505-1509.

60. Gao Q#, Bao L#, Mao H#, Wang L#, Xu K#, Yang M#, Li Y, Zhu L, Wang N, Zhe Lv, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J*, Li C*, Wang X*, Yin W*, Zhang Y*, Qin Q*. Development of an inactivated vaccine candidate for SARS-CoV-2, Science, 2020,369 (6499): 77-81.

61. Wang K#, Zhu L#, Sun Y#, Li M, Zhao X, Cui L, Zhang L, George F. Gao, Zhai W, Zhu F*, Rao Z, Wang X*. Structures of Echovirus 30 in complex with its receptors inform a rational prediction for enterovirus receptor usage, Nature Communications, 2020, 11(1): 4421.

62. Wang K#, Zheng B#, Zhang L#, Cui L, Su X, Zhang Q, Guo Z, Guo Y, Zhang W, Zhu L*, Zhu F*, Rao Z*, Wang X*. Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in Enterovirus B, Nature Communications, 2020, 11(1): 4419.

63. Yang Y#, Yang P#, Wang N, Chen Z, Su D, Zhou ZH, Rao Z*, Wang X*. Architecture of the herpesvirus genome-packaging complex and implications for DNA translocation, Protein Cell, 2020, 11(5): 339-351.

64. Wang N#, Chen W#, Zhu L#, Zhu D, Feng R, Wang J, Zhu B, Zhang X, Chen X, Liu X, Yan R, Ni D, Grace Zhou G, Liu H*, Rao Z*, Wang X*. Structures of the portal vertex reveal essential protein-protein interactions for Herpesvirus assembly and maturation, Protein Cell, 2020, 11(5): 366-373.

2019年度

65. Wang N#, Zhao D#, Wang J#, Zhang Y#, Wang M, Gao Y, Li F, Wang J, Bu Z*, Rao Z*, Wang X*. Architecture of African swine fever virus and implications for viral assembly, Science, 2019, 366(6465): 640-644.

66. Cao L#, Liu P#, Yang P, Gao Q, Li H, Sun Y, Zhu L, Lin J, Dan S*, Rao Z*, Wang X*. Structural basis for neutralization of hepatitis A virus informs a rational design of highly potent inhibitors, PLoS Biology, 2019, 17(4): e3000229.

2018年度

67. Yuan S#, Wang J#, Zhu D#, Wang N, Gao Q, Chen W, Wang J*, Zhang X*, Liu H*, Rao Z*, Wang X*. Cryo-EM structure of a Herpesvirus capsid at 3.1A, Science, 2018, 360 (6384): 48-58.

68. Zhu L#*, Sun Y#, Fan J#, Zhu B, Cao L, Gao Q, Zhang Y*, Liu H, Rao Z*, Wang X*. Structures of Coxsackievirus A10 unveil the molecular mechanisms of receptor binding and viral uncoating, Nature Communications, 2018, 9(1): 4985.

69. Wang J#, Yuan S#, Zhu D#, Tang H, Wang N, Chen W, Gao Q, Li Y, Wang J, Liu H*, Zhang X*, Rao Z*, Wang X*. Structure of the herpes simplex virus type 2 C-capsid with capsid-vertex-specific component, Nature Communications, 2018, 9: 3668.

70. Qiu X#, Lei Y#, Yang P, Gao Q, Wang N, Cao L, Yuan S, Huang X, Deng Y, Ma W, Ding T, Zhang F, Wu X, Hu J, Liu S, Qin C, Wang X*, Xu Z*, Rao Z*. Structural basis for neutralization of Japanese encephalitis virus by two potent therapeutic antibodies, Nature Microbiology, 2018, 3: 287-294.

71. Huo Y#*, Li T, Wang N, Dong Q, Wang X*, Jiang T*. Cryo-EM structure of Type III-A CRISPR effector complex, Cell Research, 2018, 28: 1195-1197.

72. Zhu L#, Xu K#, Wang N#, Cao L, Wu J, Gao Q, Fry E.E, Stuart D.I, Rao Z, Wang J, Wang X*. Neutralization Mechanisms of Two Highly Potent Antibodies against Human Enterovirus 71, mBio, 2018, 9: e01013-18.

2017年度

73. Wang X#*, Zhu L#, Dang M#, Hu Z#, Gao Q, Yuan S, Sun Y, Zhang B, Ren J, Kotecha A, Walter T.S, Wang J*, Fry E.E*, Stuart D.I*, Rao Z*. Potent neutralization of hepatitis A virus reveals a receptor mimic mechanism and the receptor recognition site, Proc.Natl.Acad.Sci.USA, 2017, 114: 770-775.

74. Wang X#*, Li S#, Zhu L#, Nian Q#, Yuan S, Gao Q, Hu Z, Ye Q, Li X, Xie D, Shaw N, Wang J, Walter T.S, Huiskonen J.T, Fry E.E, Qin C*, Stuart D.I*, Rao Z*. Near-atomic structure of Japanese encephalitis virus reveals critical determinants of virulence and stability, Nature Communications, 2017, 8: 14.

75. Zhang X#, Yang P#, Wang N, Zhang J, Li J, Guo H, Yin X, Rao Z, Wang X*, Zhang L*. The binding of a monoclonal antibody to the apical region of SCARB2 blocks EV71 infection, Protein & Cell, 2017, 8: 590-600.

 

(资料来源:王祥喜研究员,2026-11-16)

 

工作人员
研究生
离职人员
毕业学生